Regeneron Pharmaceuticals (NQ:REGN)

755.90 +18.90 (+2.56%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Price and Volume

Volume	1,427,899
Open	736.01
Bid (Size)	755.50 (80)
Ask (Size)	757.00 (40)
Prev. Close	737.00
Today's Range	735.74 - 764.09
52wk Range	476.49 - 800.99
Shares Outstanding	91,779,465
Dividend Yield	0.23%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Via StockStory

3 Nasdaq 100 Stocks We Keep Off Our Radar

November 21, 2025

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing...

Via StockStory

Performance

YTD	+5.7%	+5.7%
1 Month	+29.3%	+29.3%
3 Month	+28.2%	+28.2%
6 Month	+28.5%	+28.5%
1 Year	+1.5%	+1.5%

More News

Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗

November 20, 2025

Via Chartmill

Tech Stocks Fall Despite Nvidia's Beat, Walmart Jumps 6%: What's Moving Markets Thursday? ↗

November 20, 2025

Via Benzinga

What's going on in today's session: S&P500 movers ↗

November 20, 2025

Via Chartmill

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss ↗

November 20, 2025

Via Benzinga

Which S&P500 stocks are moving before the opening bell on Thursday? ↗

November 20, 2025

Via Chartmill

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

November 19, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Wall Street Braces for Impact as Delayed Jobs Report Emerges from Data Blackout

November 19, 2025

Via MarketMinute

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

November 19, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Pharmaceuticals (NASDAQ:REGN) Screens as a Compelling Value Investment ↗

November 18, 2025

Via Chartmill

Discover which S&P500 stocks are making waves on Monday. ↗

November 17, 2025

Via Chartmill

1 S&P 500 Stock with Exciting Potential and 2 We Question

November 16, 2025

Via StockStory

Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks ↗

November 14, 2025

Via Benzinga

What's going on in today's session: S&P500 movers ↗

November 13, 2025

Via Chartmill

The Tech Tsunami: How Breakthroughs in AI, Quantum, and Green Energy Are Reshaping the Stock Market

November 14, 2025

Via MarketMinute

Wall Street Falls On US Government Reopening Day, Bitcoin Slides To $100,000: What's Moving Markets Thursday? ↗

November 13, 2025

Via Benzinga

Tech Sector Tremors: Is the AI Bubble Deflating, and What's Next for the Market?

November 13, 2025

Via MarketMinute

Explore the top gainers and losers within the S&P500 index in today's session. ↗

November 13, 2025

Via Chartmill

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

November 13, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Here Are the Top Growth Healthcare Stocks Every New Investor Should Know ↗

November 13, 2025

Via The Motley Fool

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗

November 11, 2025

Via Benzinga

Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack

November 10, 2025

Via StockStory

Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks

November 10, 2025

Via StockStory

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% ↗

November 08, 2025

Via Investor's Business Daily

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?

Yes, Regeneron Pharmaceuticals is publicly traded.

What exchange does Regeneron Pharmaceuticals trade on?

Regeneron Pharmaceuticals trades on the Nasdaq Stock Market

What is the ticker symbol for Regeneron Pharmaceuticals?

The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market

What is the current price of Regeneron Pharmaceuticals?

The current price of Regeneron Pharmaceuticals is 755.90

When was Regeneron Pharmaceuticals last traded?

The last trade of Regeneron Pharmaceuticals was at 11/21/25 04:00 PM ET

What is the market capitalization of Regeneron Pharmaceuticals?

The market capitalization of Regeneron Pharmaceuticals is 69.38B

How many shares of Regeneron Pharmaceuticals are outstanding?

Regeneron Pharmaceuticals has 69B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.